Abstract:Introduction Different autoimmune conditions have been described in human immunodeficiency virus (HIV) patients on antiretroviral therapy (ART), but muscle-specific kinase (MuSK) myasthenia gravis (MG) coexisting with HIV is rare. We report a case of a Chinese patient with an asymptomatic HIV infection who presented with newly-onset MuSK MG and was managed successfully with the acetylcholinesterase inhibitor pyridostigmine. Case report A 71-year-old Chinese male from Zhejiang province had an established HIV infection and was on ART since 2014. He presented to the outpatient clinic stating that for the last 5 days he had been experiencing double ptosis, weakness in the neck, and difficulty to hold up his head, which were all worsening in the evening. He had been on ART consisting of Zidovudine 300 mg BID, Lamivudine 300 mg QD, and Nevirapine 200 mg BID. Although he was diagnosed and started on ART in 2014, he was subsequently followed up and had undetected viral loads with CD4 counts of 100–150 cells/μL in 2017. So, the highly active antiretroviral therapy (HAART) was changed in October 2017, and subsequently consisted of Tenofovir 300 mg QD, Lamivudine 300 mg QD, and Efavirenz 600 mg QD. His CD4 counts had increased to 183 cells/μL by April 2018. He had hypertension since 1999 and was treated with L-amlodipine and irbesartan. He had type 2 diabetes since 1999 and was treated with insulin aspartate and insulin glargine. Review of other systems was negative. On examination, he had bilateral ptosis with serious left ptosis covering the inferior margin of the pupil, and cervical extensors were at 4-strength. Fatigue tests of bilateral palpebral muscles were positive and the bilateral tendon reflex was positive. Other cranial nerves were intact. Motor, sensory, coordination, and other deep-tendon reflexes were normal. Routine blood tests, creatinine kinase, anti-nuclear antibody, anti-neutrophil cytoplasmic antibodies, rheumatoid factor, thyroid function, and anti-thyroid antibodies were normal. Total IgG titers were mildly elevated (1878 mg/dL, reference range 800–1800 mg/dL, and IgA, IgM, C3, and C4 were within normal limits. Hepatitis C antibodies were negative. Brain magnetic resonance imaging did not show any neurological abnormalities and computerized tomographic scanning of the chest did not show any significant enlargement of the thymus. His acetylcholine receptor (AChR) antibodies were negative, while MuSK antibodies were 12.00 U/mL (MuSK autoantibody titer along with cutoff 0.40 U/mL). Repetitive nerve stimulation tests (3 Hz) showed normal findings. He received oral pyridostigmine therapy (360 mg daily) soon after diagnosis of MuSK antibody-positive MG in September 2018, which resulted in resolution of ptosis and bulbar symptoms and incomplete improvement of neck weakness. However, he experienced double ptosis and weakness in the neck again when pyridostigmine was reduced to a daily dosage of 180 mg in February 2019. So, the dose of oral pyridostigmine was reduced slowly and he responded to oral pyridostigmine therapy with daily dosages of 240–180 mg from February to June 2019. By July 2019, all his symptoms had improved dramatically and pyridostigmine was stopped. He experienced continuous improvement of CD4+ T cells (202 cells/μL) with undetectable HIV viral loads. Up to January 2020, none of his symptoms reappeared. Discussion MG is an autoimmune disease that is associated with antibodies affecting the postsynaptic membrane at the neuromuscular junction.1,2 80% of MG patients have detectable antibodies against AChR, while a minority has antibodies against MuSK and lipoprotein-receptor-related protein 4.2 Overall, 1%–10% of the MG patients have serum MuSK antibodies.1 MuSK is a protein expressed in the postsynaptic muscle membrane and linked to AChR to maintain AChR function. MuSK MG is estimated to have a prevalence of 2.9 per million people in Europe.3 In China, MuSK MG is more common in the north.4 Although MG is one of the best-characterized and understood autoimmune disorders, comorbidity of HIV and MG is rare and mostly reported in incidental case reports.5 Hung et al.6 previously summarized the common characteristics of these comorbid HIV and MG patients: (1) MG develops in the early stage of HIV infection when the immune system is relatively intact; (2) the clinical course of MG appears to be benign and most patients show improvements along with advancing immunodeficiency; (3) serum anti-AChR antibodies are absent or show low titers; (4) there is little association of thymus hyperplasia as opposed to patients with AChR-Ab-positive myasthenia. Clinical features of MuSK MG resemble AChR-Ab MG, but MuSK MG patients show predominant involvement of cranial and bulbar muscles with increased incidence of ptosis, diplopia, and dysarthria, prominent with neck and respiratory muscle involvement and are less responsive to acetylcholinesterase inhibitors.7 MuSK MG may have a different cause and pathologic mechanism compared with AChR-Ab-positive MG.1,2 Comorbidity of HIV and MuSK MG is very rare, with only five cases previously reported, and very little is known about this association.8–12 These cases are summarized in Table 1. Among them, two are African Americans, while the other three are African, Japanese, and someone from Thailand. In our case, the MuSK MG patient with HIV infection came from Zhejiang province, in the south of China. One case report showed no MG relapse in an HIV-infected patient who was successfully treated with efavirenz-containing therapy.13 However, our patient, who was on Efavirenz-containing HAART, was just being diagnosed with MuSK MG. All these five case reports have described MuSK MG in HIV as part of immune reconstitution after antiretroviral treatment, in which MG was manifested as CD4 counts improved after HAART.8–12 A similar pattern was seen in the presentation of our patient, in whom the improvement of CD4 counts with changes of antiretroviral drug led to presentation of the symptoms. The following improvement of MG was accompanied with increasing CD4+ T cell counts. A consistent finding in patients with MuSK MG is that they have a much lower frequency of thymic pathology than patients with AChR-Ab-positive MG.14 This finding is consistent in all the aforementioned cases summarized in Table 1, including our patient. A possible explanation might be the normalization of immune regulation and the remount of CD4+ suppressor-inducer or regulatory T cells.Table 1: Comparison of case reports on MuSK myasthenia gravis and HIV.The management of patients with both HIV and MuSK MG is challenging. Immunosuppressants and immunomodulators have been used for the treatment of MuSK MG in HIV patient based on case reports, and was not entirely without risk.8–12 All of the five reported cases listed in Table 1 had similar findings along with positive MuSK antibodies and were subsequently treated with immunomodulators like cyclosporine, intravenous immunoglobulin, azathioprine, rituximab, and plasma exchange. Different from other cases of MG with worsening symptoms, our patient was managed with the acetylcholinesterase inhibitor pyridostigmine, which improved his symptoms successfully. Therefore, due to the lack of studies on treatment of MuSK MG in HIV patients, the use of steroids and immunomodulators should be cautiously evaluated in each patient. In conclusion, we propose that the relationship between HIV infection and MuSK MG is not just a coincidence. The Chinese old man with an established HIV infection developed new-onset MuSK MG when he was on Efavirenz-containing HAART. The improvement of MG was actually accompanied with increasing CD4+ T cell counts after changes of prescribed antiretroviral drugs and MG was successfully managed with the acetylcholinesterase inhibitor pyridostigmine. Further research is needed to identify the underlying immuno-pathogenesis and to prevent and treat MuSK MG in HIV patients.

Abstract:To the Editor: Motor neuron disease (MND) is a kind of progressive, fatal neurodegenerative disease involving the upper and lower motor neurons and the pyramidal tract. Currently, the etiology of MND remains unknown, and there are limited treatment strategies. Paraneoplastic syndrome (PNS) is a rare form of MND-mimic syndrome. There have been reports of MND-like clinical symptoms in patients with different types of cancer, including breast cancer, lung cancer, and lymphoma. Epidemiological studies have drawn different conclusions, some have suggested that there is no relation between site-specific cancers and the risk of incident amyotrophic lateral sclerosis (ALS), while others have found that the overall risk of cancer of any site is significantly reduced in cases with ALS.[1] However, the prevalence of tumors in Chinese MND patients and the characteristics of patients with MND concomitant tumors are unclear. From January 2010 to December 2016, 1751 patients visited the Peking University Third Hospital (PUTH) and were diagnosed with MND. According to the revised EI Escorial criteria, the diagnostic grades of these patients were possible, lab-supported probable, probable, or definite. Our patients were followed up every 3 months by either phone or face-to-face interview. The endpoint event was defined as death or invasive mechanical ventilation. This study was approved by the Ethics Committee of PUTH, Beijing, China. The study group obtained written informed consent from each patient before they participated in the study. Among 1751 MND patients, 28 (1.6%) had concurrent tumors, the proportion is lower than that of 8.7% or 10.1% reported in the literature.[2] Therefore, we considered the possibility of the missed diagnosis of tumors in our patients. The most common type of malignancy was lung cancer (n = 8, one case of small cell lung cancer, three of lung adenocarcinoma, and four of unknown pathological type), followed by lymphoma (n = 3, one case of Hodgkin lymphoma, one of mantle cell lymphoma, and one of intestinal lymphoma), breast cancer (n = 3), thyroid cancer (n = 2), esophageal cancer (n = 2), and gastric cancer (n = 2). One patient had concurrent esophageal cancer and kidney cancer. This result of lung cancer, breast cancer, and lymphoma as the most common types in MND patients is consistent with the results reported in the literature.[3] Thyroid cancer has been rarely reported, Liu et al[4] reported one paraneoplastic MND with thyroid cancer. However, current studies mostly focus on case reports, and the number of cases is small, the specific mechanism remains unclear. Whether MND is associated with abnormal autoimmunity caused by molecular mimicry between tumor-associated antigens and neuron-associated antigens still requires further investigation. A total of 64.3% (n=18) of patients were diagnosed with tumors after the diagnosis of MND, and the median time between the diagnosis of MND and tumors was 20 (interquartile range [IQR] = 64) months. In addition to motor symptoms, four (14.3%) patients had a sensory impairment, including one with severe pain, four (14.3%) had a cognitive or affective impairment, and two (7.1%) had bowel or bladder dysfunction. In a review by Mele et al,[3] the clinical features of 29 patients with paraneoplastic ALS were characteristics of combined non-motor symptoms such as sensory neuronopathy, suggesting that tumors may extensively impair motor, sensory, and advanced cortical functions. MND is currently considered a multisystem disease with extra-motor involvement. It has been reported that approximately 15% to 45% of MND patients have executive and behavioral disorders of varying degrees at different stages of the disease.[5] Patients in the study mainly manifested as memory loss, anxiety, and depression. In addition, it has been concluded that more than 60% of MND patients with sensory symptoms, including paresthesia and pain; and autonomic dysfunction[6] occurs in about one-third of patients, the most common autonomic symptoms are sweating dysfunction, urinary urgency, and constipation. Sensory and autonomic symptoms, which may arise as a result of musculoskeletal origin, psychological factors, or deposition of TAR DNA-binding protein 43, are common but modest. In clinical practice, for patients with clinical manifestations that do not conform to typical symptoms of MND, such as cognitive impairment incompatible with frontotemporal lobar degeneration, or severe pain, further examinations should be performed for tumor screening. The proportion of patients who underwent lumbar puncture in our study was approximately 18%. The low positive rate of tumor markers (16.7%) and onconeuronal antibodies (5.3%) indicates that in clinical practice, especially in the outpatient department, the etiological screening of MND patients is insufficient and that the sensitivity of markers commonly used in clinical practice is low. Therefore, highly sensitive biomarkers are still needed to assist in the early diagnosis of tumors. A total of 1723 MND patients without tumors diagnosed during the whole course of the disease, including 1092 (63.4%) males, had a mean onset age of 51.5 (standard deviation [SD] = 11.6) years, which was significantly lower than that of patients with tumors (61.9 years, SD = 9.8). Because the onset age is not comparable between the two groups and the age at onset may have an impact on lifespan, MND patients without tumors were matched to the 28 patients at a ratio of 4:1 according to sex and onset age by the propensity score matching (PSM) method. PSM is a method used to balance confounding factors between groups in observational studies, and we aimed to make confounding factors comparable between the two groups by PSM. The last follow-up was in May 2019, and the median follow-up time for patients with tumors was 37 (IQR = 69) months. The number of patients who reached the endpoint was thirteen (46.4%), of which 11 died and two underwent a tracheotomy.Totally, three patients were lost to follow-up. The median follow-up time for patients without tumors was 25.5 (IQR = 24) months, and 55 (49.1%) patients reached the endpoint. The Kaplan-Meier curve showed that the survival time of the MND patients with tumors was significantly longer than that of the patients without tumors (P = 0.006). Analysis using a Cox proportional hazards model suggested that the diagnostic delay time, interval to the second segment, presence of tumors, and treatment of MND were factors that affected survival time. After controlling for the other factors, the survival time of the patients with tumors was still longer than that of the patients without tumors (hazard ratio: 0.216, 95% confidence interval: 0.065–0.715, P = 0.012) [Figure 1]. We suggest the following possible reasons. First, two MND patients with tumors presented with flail arm syndrome (FAS)/flail leg syndrome, and two patients met the diagnostic criteria for isolated bulbar ALS (IBALS). The symptoms of these patients are confined to a certain segment for a long time, and those patients have a good prognosis. Second, some patients stabilize after tumor-targeted therapy or immunotherapy, suggesting that tumor-induced autoimmunity, or other mechanisms, such as oxidative stress, apoptosis, and methylation, plays a partial role and that the disease course is different from that of degenerative diseases.Figure 1: Survival analysis is stratified by the tumor. (A) Kaplan-Meier survival curves and log-rank test (P = 0.006). (B) Survival curve after adjusting for the diagnostic delay, interval to the second segment, and treatment of MND by Cox proportional hazards model (P = 0.012). Patients with tumors (green line) have longer survival than those without tumors (blue line). MND: Motor neuron disease.Among the 28 patients, one was diagnosed with definite PNS according to the diagnostic criteria by Graus, and 12 were diagnosed with possible PNS. The patient diagnosed with PNS was positive for the antibody amphiphysin in blood and negative in cerebrospinal fluid, but neurological symptoms after surgical resection of the lung cancer still deteriorated, not according with canonical PNS. Among the 12 possible PNS, nine could be diagnosed with typical ALS, and two were initially diagnosed with progressive bulbar palsy; however, according to the IBALS criteria, one patient could be diagnosed with IBALS, one patient with FAS. Three patients presented with symptoms other than the motor system, including cognitive and sensory impairment. The most common type of tumor was lung cancer (n = 4), followed by hematologic tumors (n = 3), thyroid cancer (n = 2), breast cancer (n = 1), prostate cancer (n = 1), and gastric cancer (n = 1). Only two patients showed MND symptoms after the tumors. In conclusion, we analyzed the clinical characteristics of patients with MND and concurrent tumors, and they were different from patients with degenerative MND in terms of clinical manifestations and disease progression. Though the cases are rare, further study is necessary to elucidate the mechanisms and direct early diagnosis and treatment strategies. Funding This study was supported by the National Natural Sciences Foundation of China (No. 81873784). Conflicts of interest None.

Association between motor neuron disease and HIV infection: A systematic review of case reports

Motor neuron disease and HIV-1 infection in a 30-year-old HIV-positive heroin abuser: a causal relationship?

MuSK Myasthenia Gravis in an HIV-infected Chinese Old Man Successfully Treated with Pyridostigmine

Neuromuscular diseases of AIDS

Human immunodeficiency virus-associated nemaline myopathy: a case report and literature review

Motor-related Brain Abnormalities in HIV-infected Patients: a Multimodal MRI Study

Molecular Role of HIV-1 Human Receptors (CCL5–CCR5 Axis) in neuroAIDS: A Systematic Review

New developments in the diagnosis and management of motor neuron disease

Epidemiological Characteristics of Motor Neuron Disease in Chinese Patients.

Genetics of Motor Neuron Disease in New Zealand

Genetics of motor neuron disorders: new insights into pathogenic mechanisms

Sex, racial, and ethnic disparities in motor neuron disease: clinical trial enrolment

Unusual demyelinating disease in a patient with HIV infection

Human immunodeficiency virus-associated vacuolar encephalomyelopathy with granulomatous-lymphocytic interstitial lung disease improved after antiretroviral therapy: a case report

Amyotrophic lateral sclerosis associated with Sjögren's syndrome: a case report

Future Directions for Diagnosis and Treatment

Neurological disorders in HIV: Hope despite challenges

Clinical Characteristics of Patients with Motor Neuron Disease and Concurrent Tumors

Clinical features in Hodgkin lymphoma patients living with human immunodeficiency virus: A meta-analysis in the antiretroviral therapy era

A Case of Varicella-Zoster Virus Meningomyelitis in an HIV-1-Infected Patient: Facing the Challenges Related to Its Management and Prognosis

Association between ALS and retroviruses: evidence from bioinformatics analysis